Has GW Pharmaceuticals – Now Jazz Pharmaceuticals – Knee-Capped The CBD Industry? February 16, 2023 Peter McCusker Europe, News & Insights 0 Comments WITH the fast-growing CBD sector tied up in a regulatory quagmire hundreds of transatlantic industry players face an uncertain future. However, one UK company – the one which pioneered the medical use of the cannabis extract cannabidiol – will have… Read More→
Epilepsy patients navigate a murky, unregulated CBD market July 13, 2022 AggregatedNews Hemp Business Executive 0 Comments The products may help some people with the neurological disorder, but obtaining the right treatments can be difficult In 2013, Tonya Taylor says, she was suicidal because her epileptic seizures kept coming even though she was taking a long list… Read More→
Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025 September 3, 2021 Peter McCusker Medical Marijuana 0 Comments COMBINED sales of the three most lucrative cannabis pharmaceuticals products – Epidiolex, Dronabinol and Sativex – are set to reach €1.8 billion by 2025, according to a new report. The Pharmaceutical Cannabis Report: 2nd Edition, from global cannabis industry consultants… Read More→
Did the DEA’s new rule confirm hemp-derived Delta-8 THC is illegal? September 1, 2020 Andrea Steel Hemp Policy & Legal, Spotlight 0 Comments By: Andrea Steel and Lisa Pittman Last Friday, the Drug Enforcement Administration (the “DEA”) published a rule regarding the scheduling of hemp and marijuana, effective immediately (the “Rule”). The cannabis community swiftly reacted with an interpretation that this Rule outlawed… Read More→
Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring August 7, 2019 AggregatedNews Cannabis Investments, Medical Marijuana, On the Move 0 Comments GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading. GW Pharmaceuticals GWPH, +10.22% reported second-quarter sales of $68.4 million for Epidiolex, which uses… Read More→
Big Pharma is Coming for the Cannabis Industry January 5, 2019 John Taenzler Medical Marijuana, Science and Technology 0 Comments In a recent double-blinded study [1] examining the attitudes of pain specialists and oncologists toward the use of MMJ, only 38% of these physicians in the USA are recommending MMJ to their patients for treating the symptoms of their disease and/or… Read More→
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress December 7, 2018 Press Release Banking, Finance & Real Estate, Press Releases, Science and Technology 0 Comments PRESS RELEASE Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine launched in the U.S. - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH,… Read More→
DEA reclassifies plant-derived marijuana medicine November 26, 2018 AggregatedNews Policy & Legal 0 Comments According to a release issued by the National Organization for the Reform of Marijuana Laws, Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified by the U.S. Drug Enforcement Administration to Schedule V — the lowest restriction… Read More→
First FDA approved cannabis-based drug now available by prescription November 2, 2018 AggregatedNews Policy & Legal 0 Comments The first cannabis-derived medication approved by the Food and Drug Administration is now available by prescription in every state, according to its manufacturer. Epidiolex, manufactured by GW Pharmaceuticals, is intended to treat seizures associated with two rare and severe forms of… Read More→
Will the FDA/DEA Epidiolex Rulings and the 2018 Farm Bill Change the Industry? October 4, 2018 Courtney Elder Hemp Industry News, Policy & Legal 0 Comments In late June 2018, the Food and Drug Administration announced approval for a new medication that could potentially change the way the world views cannabis. Epidiolex is a CBD-based oral solution that is prescribed to treat two forms of rare… Read More→
The drug maker behind the first FDA-approved medication derived from marijuana has revealed how much it’ll cost August 9, 2018 AggregatedNews Policy & Legal 0 Comments A marijuana-derived drug that recently became the first of its kind to win federal approval is not going to be cheap. Called Epidiolex, the drug is designed to treat two rare forms of childhood epilepsy using a cannabis compound called… Read More→
Buzzkill Alert: California Prohibits Hemp CBD In Food July 31, 2018 Hilary Bricken California 2 Comments California is essentially letting the FDA dictate what it will do with hemp CBD. Earlier this month, the California Department of Public Health’s Food and Drug Branch (CDPH-FDB) issued a revised FAQ on cannabidiol (CBD) in food products. Per these FAQs… Read More→
The Federal Government has acknowledged a patent on a cannabis based pharmaceutical as a legitimate and useful medicine June 29, 2018 Mark Goldfogel Op-Ed, Opinions 1 Comment G.W. Pharmaceuticals accomplished a feat that is about to change the course of history. They achieved drug approval for a plant-based medicine related to cannabis for treatment of certain conditions in children! This doesn’t apply only to states that have… Read More→
The FDA Just Approved the First-Ever Cannabis Based Drug in the U.S. June 26, 2018 AggregatedNews Policy & Legal, Science and Technology 0 Comments The Food and Drug Administration (FDA) for the first time approved a drug directly derived from cannabis on Monday, Epidiolex, developed by the British GW Pharmaceuticals. Although several states have legalized the medical and recreational use of marijuana, the federal… Read More→
Don’t Expect Joints If the FDA Ever Approves Medical Marijuana May 8, 2018 AggregatedNews Policy & Legal 0 Comments While past marijuana opponents like John Boehner are coming around to legal weed, the Food and Drug Administration isn’t likely to recommend that Americans light up a joint anytime soon. That doesn’t mean that cannabis will never be sanctioned by… Read More→